Skip to content
Assyro AI
US FDA source recordWL · Warning Letter

Sato Pharmaceutical Co., Ltd. — FDA Warning Letter

Issued to Sato Pharmaceutical Co., Ltd.. Serious post-market compliance violation.

Issued

May 18, 2026

Product

CGMP/Drugs/Adulterated/OTC

Company

Sato Pharmaceutical Co., Ltd.

Review center

CDER

Stage

Final Decision

Read source documentView similar WL records

Assyro regulatory brief

Free

Why did Sato Pharmaceutical Co., Ltd. receive an FDA warning letter?

Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.

Verify in source

Source facts

FDA issued a warning letter to Sato Pharmaceutical Co., Ltd. concerning CGMP/Drugs/Adulterated/OTC. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

Key details in this letter

  • 1Subject: CGMP/Drugs/Adulterated/OTC.
  • 2Issuing office: Center for Drug Evaluation and Research (CDER).
  • 3Manufacturing and CGMP controls: 1 source-text match.
  • 4No closeout letter was listed in the source metadata at refresh time.
Manufacturing and CGMP controls

Suggested next step

Review the exact FDA warning letter, cited violations, requested corrections, and any later response or closeout before assessing current status.

Open the document workspace

Built from structured FDA metadata and deterministic source-text signals. Topic matches are navigation aids, not legal or regulatory conclusions. Verify material decisions against the original FDA document.

FDAHTMLUpdated Jul 30, 2026

FDA source document

Read the full FDA warning letter

FDA publishes this warning letter as a web document.

Open the exact FDA source to read the complete letter and verify its current response or closeout status.

Open source on FDA.gov

Common questions about the Sato Pharmaceutical Co., Ltd. warning letter

What does this warning letter mean for Sato Pharmaceutical Co., Ltd.?

Serious post-market compliance violation. Public notice requiring prompt remediation. FDA issued this letter on May 18, 2026.

What happens after an FDA warning letter?

The firm is expected to respond in writing, normally within 15 working days, describing corrective actions and timelines. FDA verifies remediation — often through reinspection — and issues a closeout letter when violations are corrected. Unresolved warning letters can escalate to import alerts, seizure, or injunction.